Literature DB >> 1677700

Torsades de pointes ventricular tachycardia and terodiline.

M J Connolly1, P S Astridge, E G White, C A Morley, J C Cowan.   

Abstract

We report five patients (four women, one man; mean age 74 years, range 55-87) taking terodiline who had torsades de pointes ventricular tachycardia associated with prolongation of the QT interval. The QT interval was normal before the introduction of terodiline in three patients and returned to normal after terodiline withdrawal in four. Atrioventricular conduction disturbance or bradycardia were evident in all patients. Terodiline should be prescribed with caution to elderly patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1677700     DOI: 10.1016/0140-6736(91)90481-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  12 in total

1.  QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman.

Authors:  Hiroshi Asajima; Yohei Sekiguchi; Shoji Matsushima; Naotaka Saito; Takahiko Saito
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

2.  Differences in the effects of urinary incontinence agents S-oxybutynin and terodiline on cardiac K(+) currents and action potentials.

Authors:  S E Jones; L M Shuba; P Zhabyeyev; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 3.  Drug effects on the electrocardiogram. A review of their clinical importance.

Authors:  J D Symanski; L S Gettes
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 4.  Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.

Authors:  Galia Jackobson; Narin Nard Carmel; Dor Lotan; Anjelika Kremer; Dan Justo
Journal:  Z Gerontol Geriatr       Date:  2016-11-22       Impact factor: 1.281

5.  CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system.

Authors:  G A Ford; S M Wood; A K Daly
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

6.  Terodiline causes polymorphic ventricular tachycardia due to reduced heart rate and prolongation of QT interval.

Authors:  D A Stewart; J Taylor; S Ghosh; G J Macphee; I Abdullah; J M McLenachan; D J Stott
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

7.  Block and modified gating of cardiac calcium channel currents by terodiline.

Authors:  T Ogura; S Jones; L M Shuba; J R McCullough; T F McDonald
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

8.  Electrophysiological profile of propiverine--relationship to cardiac risk.

Authors:  Torsten Christ; Erich Wettwer; Melinda Wuest; Manfred Braeter; Frank Donath; Pascal Champeroux; Serge Richard; Ursula Ravens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-19       Impact factor: 3.000

Review 9.  Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.

Authors:  Rashmi R Shah
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

10.  Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence.

Authors:  S H Thomas; P D Higham; K Hartigan-Go; F Kamali; P Wood; R W Campbell; G A Ford
Journal:  Br Heart J       Date:  1995-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.